5-Amino-1mq Clinical Trial

Clinical Status of 5-Amino-1MQ: Human Trials vs. Preclinical Data

As of current scientific literature and clinical registry databases, there are no published or completed human 5-amino-1mq clinical trials. 5-Amino-1MQ remains strictly a preclinical research compound and selective nicotinamide N-methyltransferase (NNMT) inhibitor utilized exclusively in vitro and in animal models to study cellular energy expenditure, NAD+ conservation, and metabolic kinetics.

Formal clinical evaluation in humans requires structured Investigational New Drug (IND) filings, Phase I pharmacokinetic and safety profiling, and oversight by institutional review boards. Because public interest in metabolic modulation often generates queries regarding human clinical trial outcomes, institutional researchers must distinguish between published rodent models and human medical testing. To date, all empirical data evaluating 5-Amino-1MQ originate from primary cell cultures, immortalized cell lines, and murine models of diet-induced obesity.

For ongoing laboratory protocols, investigators can procure high-purity 5-Amino-1MQ as an analytical reference standard. In vitro screening platforms continue to map its kinetic selectivity against related methyltransferases before any formal human clinical translation can be considered.

Molecular Mechanism: Enzymatic Inhibition of NNMT

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). Because NAM serves as a direct precursor in the salvage pathway for nicotinamide adenine dinucleotide (NAD+), hyperactive NNMT expression acts as a metabolic sink, draining intracellular NAM pools and suppressing total NAD+ availability.

5-Amino-1MQ was designed as a membrane-permeable, small-molecule inhibitor targeting the substrate-binding pocket of NNMT. By selectively inhibiting NNMT activity, 5-Amino-1MQ prevents the irreversible clearance of NAM, effectively shifting cellular metabolic flux back toward endogenous NAD+ resynthesis. Investigators assessing cellular bioenergetics utilize various metabolic research compounds to track changes in intracellular metabolite ratios via high-performance liquid chromatography and mass spectrometry (LC-MS/MS).

Preclinical Findings on NAD+ Elevation and Methyl Donor Balance

In cell culture assays using differentiated adipocytes and myocytes, application of 5-Amino-1MQ leads to a statistically significant increase in intracellular NAD+ levels. This elevation in NAD+ concentration supports the activity of downstream NAD+-dependent enzymes, most notably the sirtuin family (SIRT1–SIRT7) and poly(ADP-ribose) polymerases (PARPs). Sirtuins, particularly SIRT1 and SIRT3, play crucial roles in regulating mitochondrial biogenesis, histone deacetylation, and transcriptional networks linked to oxidative metabolism.

Beyond preserving NAM for NAD+ synthesis, NNMT inhibition alters the SAM/SAH methyl donor ratio within the cell. High NNMT expression depletes SAM, which can impair histone methyltransferase activity and alter epigenetic regulation. Preclinical studies suggest that treatment with 5-Amino-1MQ restores cellular methyl donor availability, thereby influencing histone methylation patterns and gene expression profiles involved in lipid storage and energy turnover.

Mitochondrial Output and Adipose Tissue Remodeling in Animal Models

In vivo animal studies employing high-fat diet (HFD) rodent models demonstrate that elevated NNMT expression in white adipose tissue (WAT) correlates strongly with metabolic dysfunction and obesity. When administered 5-Amino-1MQ, high-fat fed mice exhibited reduced weight gain, diminished adipocyte hypertrophy, and improved systemic insulin sensitivity compared to untreated control cohorts, without displaying alterations in daily food intake.

In vitro and ex vivo tissue analyses indicate that 5-Amino-1MQ promotes a phenotypic shift in white adipocytes toward a thermogenic, brown-like adipocyte state—a process commonly termed adipose tissue browning. Characterized by upregulated expression of Uncoupling Protein 1 (UCP1) and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PGC-1α), this remodeling increases basal mitochondrial respiration and maximal oxygen consumption rates, facilitating elevated fatty acid oxidation.

Comparative Analysis: Parallel Research Pathways in Metabolic Regulation

When evaluating small molecules and peptides in metabolic research models, investigators often compare 5-Amino-1MQ against parallel mechanisms targeting cellular bioenergetics. While 5-Amino-1MQ functions specifically as a direct enzymatic inhibitor of NNMT to conserve endogenous NAD+, mitochondrial-derived signaling peptides such as MOTS-c operate via nuclear translocation to modulate folate metabolism and activate AMPK signaling. Similarly, synthetic nuclear receptor agonists like SLU-PP-332 target estrogen-related receptors (ERRs) to promote oxidative muscle fiber transition, whereas specialized fragment peptides like AOD-9604 act through lipolytic domain interaction with growth hormone pathways. Researchers evaluating direct metabolite supplementation also examine co-substrates like NAD+ to contrast direct pool loading against enzymatic degradation blocking.

Understanding these distinct mechanism classes allows laboratory directors to select complementary compounds for multi-target in vitro assays. Detailed structural breakdowns and kinetic comparisons are cataloged in our comprehensive guide to NNMT inhibitors and metabolic pathways.

In Vitro and In Vivo Experimental Methodologies

Preclinical investigation of 5-Amino-1MQ relies on standard analytical and cell-based experimental models. In vitro protocols commonly utilize 3T3-L1 preadipocytes, primary human subcutaneous adipocytes, or C2C12 myotubes. Key endpoints include determining half-maximal inhibitory concentration (IC50) values against recombinant human NNMT, measuring changes in intracellular NAD+/NADH ratios using enzymatic fluorometric assays, and quantifying mitochondrial oxygen consumption rates (OCR) via extracellular flux analyzers.

In vivo animal models typically utilize male C57BL/6J mice maintained on a 60% high-fat diet. Dosing protocols published in literature evaluate pharmacokinetic parameters such as plasma half-life, tissue distribution across visceral and subcutaneous adipose depots, and metabolic marker clearance. All such methodologies serve strictly to characterize pharmacological mechanisms in preclinical settings.

Reconstitution, Solubilization, and Laboratory Handling

5-Amino-1MQ is supplied as a highly purified solid powder. For long-term storage stability, lyophilized compound should be stored desiccated at -20°C or -80°C, protected from ambient light and atmospheric moisture. Standard laboratory protocol requires equilibrating the vial to room temperature prior to opening to prevent moisture condensation on the dry powder.

For cell culture or enzymatic assays, 5-Amino-1MQ exhibits optimal solubility in organic solvents such as dimethyl sulfoxide (DMSO). Laboratory staff should prepare concentrated stock solutions in DMSO, which can be stored in single-use aliquots at -80°C. When diluting stock solutions into aqueous culture media or reaction buffers, ensure the final DMSO concentration remains below cytotoxic thresholds (typically <0.1% v/v in cell culture) to prevent solvent-induced experimental artifacts.

Analytical Verification and Quality Control Metrics

Because small-molecule NNMT inhibitors are sensitive to residual reaction intermediates and counter-ion imbalance, obtaining rigorous analytical verification is critical for reproducible research. Sub-standard chemical purity can cause off-target cytotoxicity, enzyme inhibition artifacts, and unrepeatable bioenergetic measurements in vitro.

PX1 Research ensures that every production lot of 5-Amino-1MQ undergoes rigorous testing at an independent, ISO 17025 accredited laboratory in the USA. Each lot is issued a comprehensive Certificate of Analysis (COA) confirming chemical identity via Mass Spectrometry (MS) and purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), consistently verifying chemical purity equal to or exceeding 98%.

Endotoxin Control and Procurement Standards at PX1 Research

In addition to structural identity and chromatographic purity, controlling endotoxin contamination is paramount for metabolic and cell culture assays. Bacterial lipopolysaccharides (LPS) trigger inflammatory signaling cascades through Toll-like receptor 4 (TLR4), which can suppress mitochondrial respiration and distort metabolic gene expression. PX1 Research subjects all compound batches to quantitative chromogenic Limulus Amebocyte Lysate (LAL) testing to guarantee endotoxin levels remain well within strict laboratory thresholds.

Manufactured in state-of-the-art U.S. facilities following cGMP-compliant processes, PX1 Research products ship directly from distribution hubs in California and Arizona. Orders placed Monday through Friday before cut-off times qualify for same-day dispatch. Institutional laboratories requiring high-volume supplies or reserved single-lot batches can utilize our dedicated wholesale laboratory program.